The startup develops genetic medicines that target multiple pathways through the upregulation of specific non-coding RNAs to regenerate heart tissue damaged by ischemic heart disease. This approach enables healthcare professionals to restore heart function and improve patient outcomes effectively.
Funding
$8.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Ischemic heart disease, often resulting in myocardial infarction, leads to irreversible damage to heart tissue and subsequent heart failure, representing a leading cause of death worldwide. Current treatments primarily focus on managing symptoms and preventing further damage, but lack the ability to regenerate damaged heart tissue and restore full cardiac function.
Solution
Heqet Therapeutics is developing first-in-class, non-coding RNA-based therapeutics designed to regenerate heart tissue damaged by acute myocardial infarction and other cardiovascular diseases. Their compounds target multiple pathways by upregulating specific non-coding RNAs, including factors in the Hippo pathway (TAOK1 and β-TrCP) and the actin cytoskeleton regulatory protein cofilin-2. This approach aims to stimulate cardiac repair and improve heart function, addressing a significant unmet need in patients with heart failure. The company's vision is to establish a new standard of care for myocardial infarction-induced regeneration.
Target Audience
The primary target audience includes patients suffering from acute myocardial infarction and other cardiovascular diseases, as well as healthcare professionals seeking novel therapies for cardiac regeneration.
Features
- Utilizes non-coding RNA-based compounds to stimulate cardiac regeneration.
- Targets multiple pathways involved in heart tissue repair, including the Hippo pathway and actin cytoskeleton regulation.
- Employs lipid nanoparticle (LNP)-based delivery systems for targeted delivery of therapeutics.
- Focuses on addressing acute myocardial infarction and other cardiovascular diseases.
- Compounds are designed to upregulate specific non-coding RNAs to promote heart tissue regeneration.
- Developing first-in-class compounds for cardiac regeneration.